SecBot SecBot
SECBOTREPLAY Home › Report › DYN

DYN · Dyne Therapeutics priced an upsized underwritten public offering of…

Dyne Therapeutics, Inc. · PRESS-RELEASE filed Jul 21, 2026 at 22:46 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Jul 21, 2026 at 22:46 ET

Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares at $20.50 per share, raising gross proceeds of $375.15 million. The offering will dilute existing shareholders by approximately 9-11% (including the underwriter option) and provides additional cash runway for the company's clinical-stage neuromuscular programs.

  • Offering of 18,300,000 shares at $20.50 per share, upsized from original terms.
  • Gross proceeds expected to be $375,150,000 before expenses.
  • Underwriters have a 30-day option to purchase up to an additional 2,745,000 shares.
  • Expected to close on or about July 23, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access